Author

Jasmina Kalabic 1

1 AbbVie Deutschland GmbH & Co. KG,Ludwigshafen,Germany

A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

Marc Ferrante, Valerie Pivorunas, James Butler, Naim Mahi, Nael M. Mostafa, Melanie Ruzek, James Fann, Feng Hong, Xiaohong Cao, Nizar Smaoui, Justin Wade Davis, Jasmina Kalabic, Alexandra Song, Heath M. Guay, Florian Rieder, Julian Panés, Jean-Frédéric Colombel

ADALIMUMAB LONG-TERM EFFECTIVENESS IN ADALIMUMAB-NAIVE PATIENTS WITH CROHN'S DISEASE: FINAL DATA FROM PYRAMID REGISTRY

Edward V Loftus Jr, Geert R. D'Haens, Walter Reinisch, Jack Satsangi, Remo Panaccione, Sofie Berg, Gabriela Alperovich, Mareike Bereswill, Jasmina Kalabic, Martha Skup, Joel Petersson, Anne M. Robinson

EFFICACY AND SAFETY OF ADALIMUMAB IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Baili CHEN, Xiang Gao, Jie Zhong, Jianlin Ren, Xuan Zhu, Zhanju Liu, Kaichun Wu, Jasmina Kalabic, Bidan Huang, Thao Doan, Anne M. Robinson, Minhu Chen

High versus standard adalimumab induction dosing regimens in patients with moderately to severely active ulcerative colitis: results from the SERENE-UC induction study

Julian Panés, Jean-Frédéric Colombel, Geert R. D'Haens, Stefan Schreiber, Remo Panaccione, Laurent Peyrin-Biroulet, Edward Loftus, Silvio Danese, Edouard Louis, Alessandro Armuzzi, Marc Ferrante, Harald Vogelsang, Jessica Lefebvre, Thao Doan, Nisha V. Kwatra, Nael M. Mostafa, Wangang Xie, Bidan Huang, Joel Petersson, Jas

Long-term effect of risankizumab on improved and sustained health-related quality of life over 3 years in patients with moderate to severe Crohn's disease: interim analysis of a phase 2 open-label extension study

Edouard Louis, Peter Bossuyt, Julian Panés, Brian G. Feagan, Jasmina Kalabic, Kori Wallace, Naijun Chen, Wan-Ju Lee, Marc Ferrante

LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: 3-YEAR INTERIM RESULTS FROM THE ONGOING PHASE 2 OPEN-LABEL EXTENSION STUDY

Jasmina Kalabic

Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: 3-year interim results from the ongoing Phase 2 open-label extension study

Marc Ferrante, Brian G. Feagan, Julian Panés, Filip Baert, Edouard Louis, Olivier Dewit, Arthur Kaser, Weijiang Rachel Duan, Dawn Gustafson, Xiaomei Liao, Kori Wallace, Jasmina Kalabic, Geert R. D'Haens

LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: INTERIM RESULTS OF THE ONGOING PHASE 2 OPEN-LABEL EXTENSION STUDY

Marc Ferrante, Julian Panés, Filip Baert, Edouard Louis, Arthur Kaser, Dawn Gustafson, David Hall, Wulf O. Böcher, Ivona Herichova, Xiaomei Liao, Kori Wallace, Jasmina Kalabic, Geert R. D'Haens

MECHANISMS OF NON-RESPONSE TO ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE: PERIPHERAL PROTEOMIC AND TRANSCRIPTOMIC PROFILING FROM THE SERENE-CD AND SERENE-UC STUDIES

Julian Panés, Bram Verstockt, Valerie Pivorunas, James Butler, Naim Mahi, Melanie Ruzek, Thierry Sornasse, James Fann, Feng Hong, Xiaohong Cao, Nizar Smaoui, Justin Wade Davis, Jasmina Kalabic, Alexandra Song, Heath M. Guay, Azucena Salas, Nick Kennedy, Tariq Ahmad, Severine Vermeire

PYRAMID REGISTRY: LONG-TERM SAFETY AND EFFECTIVENESS OF ADALIMUMAB BY BASELINE IMMUNOMODULATOR USE IN PATIENTS WITH CROHN’S DISEASE

Walter Reinisch, Remo Panaccione, Geert R. D'Haens, Edward V Loftus Jr, Jack Satsangi, Jean-Frederic Colombel, Gabriela Alperovich, Sofie Berg, Jasmina Kalabic, Mareike Bereswill, Joel Petersson, Anne M. Robinson

Item 1 - 10 / 12
1
2